Janssen JC, Woythal N, Meissner S, Prasad V, Brenner W, Diederichs G, Hamm B, Makowski MR (2017)
Publication Type: Journal article
Publication year: 2017
Book Volume: 19
Pages Range: 933-943
Journal Issue: 6
DOI: 10.1007/s11307-017-1101-y
Purpose: The aim of this study was to evaluate potential differences in “Glu-NH-CO-NH-Lys” radio-labeled with [68Ga]gallium N,N-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N-diacetic acid ([68Ga]PSMA-HBED-CC) uptake in osteolytic, osteoblastic, mixed, and bone marrow metastases in prostate cancer (PC) patients. Procedures: This retrospective study was approved by the local ethics committee. Patients who received [68Ga]PSMA-HBED-CC positron emission tomography/computed tomography ([68Ga]PSMA-PET/CT) with at least one positive bone metastasis were included in this study. Only patients who have not received systemic therapy for their PC were included. Bone metastases had to be confirmed by at least one other imaging modality or follow-up investigation. The maximum standardized uptake value (SUV
APA:
Janssen, J.-C., Woythal, N., Meissner, S., Prasad, V., Brenner, W., Diederichs, G.,... Makowski, M.R. (2017). [68Ga]PSMA-HBED-CC Uptake in Osteolytic, Osteoblastic, and Bone Marrow Metastases of Prostate Cancer Patients. Molecular Imaging and Biology, 19(6), 933-943. https://doi.org/10.1007/s11307-017-1101-y
MLA:
Janssen, Jan-Carlo, et al. "[68Ga]PSMA-HBED-CC Uptake in Osteolytic, Osteoblastic, and Bone Marrow Metastases of Prostate Cancer Patients." Molecular Imaging and Biology 19.6 (2017): 933-943.
BibTeX: Download